| 56.9 0.69 (1.23%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 69.75 | 1-year : | 81.47 |
| Resists | First : | 59.72 | Second : | 69.75 |
| Pivot price | 56.89  |
|||
| Supports | First : | 53.69 | Second : | 49.97 |
| MAs | MA(5) : | 56.99  |
MA(20) : | 56.16 |
| MA(100) : | 52.79 |
MA(250) : | 46.47 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 47.6 |
D(3) : | 53.3 |
| RSI | RSI(14): 54 |
|||
| 52-week | High : | 59.72 | Low : | 33.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ EXEL ] has closed below upper band by 49.9%. Bollinger Bands are 1.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 57.02 - 57.24 | 57.24 - 57.49 |
| Low: | 54.36 - 54.59 | 54.59 - 54.86 |
| Close: | 56.46 - 56.84 | 56.84 - 57.28 |
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Mon, 14 Sep 2026
Exelixis, Inc. (EXEL) Stock Analysis: Evaluating Growth Potential Amidst a Competitive Biotech Landscape - DirectorsTalk Interviews
Mon, 14 Sep 2026
Exelixis: The FDA Delay Costs Less Than The Market Thinks (NASDAQ:EXEL) - Seeking Alpha
Fri, 11 Sep 2026
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In - Benzinga
Mon, 07 Sep 2026
Exelixis, Inc. (EXEL) Stock Analysis: A Promising Biotech with Robust Revenue Growth and Strategic Partnerships - DirectorsTalk Interviews
Tue, 01 Sep 2026
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September - Business Wire
Wed, 05 Aug 2026
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 248 (M) |
| Shares Float | 214 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 107 (%) |
| Shares Short | 28,030 (K) |
| Shares Short P.Month | 30,910 (K) |
| EPS | 3.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.4 |
| Profit Margin | 35.3 % |
| Operating Margin | 39.5 % |
| Return on Assets (ttm) | 23.9 % |
| Return on Equity (ttm) | 44.3 % |
| Qtrly Rev. Growth | 10.6 % |
| Gross Profit (p.s.) | 9.48 |
| Sales Per Share | 9.84 |
| EBITDA (p.s.) | 4.11 |
| Qtrly Earnings Growth | 26.2 % |
| Operating Cash Flow | 1,180 (M) |
| Levered Free Cash Flow | 740 (M) |
| PE Ratio | 17.89 |
| PEG Ratio | 2.5 |
| Price to Book value | 7.67 |
| Price to Sales | 5.77 |
| Price to Cash Flow | 11.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|